Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Nuvation Bio Inc. Class A Common Stock trades at $4.71 (market cap $1.66B). The key difference: Nuvation Bio Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nuvation Bio Inc. Class A Common Stock for 6 Days on average.
| MRVI | NUVB | |
|---|---|---|
Market Cap | $972.90M | $1.66B |
Volume | 4,325,710 | 7,608,075 |
Sector | Health | Health |
52-Week High | $9.00 | $9.54 |
52-Week Low | $2.83 | $3.41 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $1.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
